Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells

Min Lu, Jiapeng Wang, Yan Li, Dmitriy Berenzon, Xiaoli Wang, John Mascarenhas, Mingjiang Xu, Ronald Hoffman

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Fingerprint

Dive into the research topics of 'Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds